History

Testosterone was first isolated and synthesized in 1935 and is a long-established, FDA-approved medicine. The 17α-alkylated oral methyltestosterone has been marketed since the early 1940s; injectable esters followed, and modern transdermal gels (e.g., AndroGel, approved 2000) and an oral testosterone undecanoate product (Jatenzo, approved 2019) are also FDA-approved. Its approved use is replacement therapy for male hypogonadism due to disorders of the testes, pituitary, or hypothalamus — not for low testosterone attributed solely to aging.

Testosterone is the body’s principal androgen and the molecule from which the entire class of anabolic-androgenic steroids (AAS) is derived. It is a steroid, not a peptide. It has decades of FDA-approved medical use as replacement therapy for men with confirmed hypogonadism, and the human evidence that it builds muscle and strength is among the strongest for any performance agent. But it is a Schedule III controlled substance, banned in sport at all times, and carries genuine cardiovascular, hematologic, hormonal, and (for certain oral forms) hepatic risks. This page is educational and harm-reduction oriented; it contains no doses, cycles, ester schedules, stacks, post-cycle protocols, or sourcing information.

What it is

Testosterone is the principal endogenous androgen — a C19 steroid (4-androsten-17β-ol-3-one) and the prototypical anabolic-androgenic steroid; the other AAS are synthetic derivatives of it. Mechanistically, it is an agonist of the nuclear androgen receptor (AR). The testosterone–AR complex translocates to the cell nucleus and modulates gene transcription, driving anabolic effects in skeletal muscle and androgenic/virilizing effects in secondary sex tissues. Testosterone is also a prohormone: it is reduced by 5α-reductase to the more potent androgen dihydrotestosterone (DHT, which drives prostate, skin, and hair effects), and aromatized by aromatase (CYP19) to estradiol (which contributes to bone, libido, and some adverse effects such as gynecomastia).

The pharmaceutical forms differ in important ways:

Native (unesterified) testosterone is cleared too quickly when taken orally to be practical, so it is delivered transdermally (gels/patches), as a buccal/nasal product, or as a pellet implant.
Injectable esters (e.g., enanthate, cypionate, undecanoate) are testosterone esterified at the 17β-hydroxyl. The ester is cleaved in the body to release free testosterone, slowing release from an oil depot to prolong action. Esterification is a delivery strategy and does not make the molecule liver-toxic.
17α-alkylated (17-aa) orals (e.g., methyltestosterone) carry a methyl group at C17 that resists hepatic first-pass metabolism, making them orally active — at the cost of dose-dependent hepatotoxicity. Native injectable testosterone esters are not 17α-alkylated and do not share this hepatotoxic mechanism. Most modern testosterone therapy is non-17-aa.

The claims

Medical: Testosterone is approved and used as replacement therapy in confirmed male hypogonadism, and is also used in delayed puberty in boys and certain other endocrine settings. (Limited use in some gender-affirming and select female conditions is outside the scope of this page.)

Athletic and bodybuilding (non-medical): Testosterone is used off-label, generally without a prescription, to increase lean mass and strength and to support recovery. This use is prohibited in sport.

What the evidence actually shows

The evidence that testosterone builds muscle and strength in humans is unusually robust.

Supraphysiologic testosterone increases muscle and strength even without training, and adds to training. In a landmark randomized controlled trial (Bhasin et al., NEJM 1996; 43 healthy men, 10 weeks), testosterone groups gained fat-free mass, muscle size, and bench-press and squat strength versus placebo; testosterone plus exercise produced the largest gains (PMID 8637535).
Effects are dose-dependent. Graded-dose studies showed dose-related increases in fat-free mass, muscle size, and leg-press strength and power (Bhasin et al., Am J Physiol Endocrinol Metab 2001; PMID 11701431).
Older men respond too. In healthy older men, testosterone increased lean mass and muscle strength and power, and older men were as responsive as younger men to graded doses (Bhasin et al., J Clin Endocrinol Metab 2005; PMID 15562020).
In hypogonadal and older men, replacement produces modest, real gains in lean mass, muscle strength, and some physical-function and sexual-function measures, but effects on harder clinical endpoints (e.g., vitality, cognition) are smaller and less consistent. The coordinated Testosterone Trials (TTrials) in men aged 65 and older with low testosterone are the key body of evidence here (Snyder et al., NEJM 2016; PMID 26886521).

Bottom line on efficacy: strong, reproducible evidence for lean-mass and strength gains, which are dose-dependent; benefits on hard clinical and functional outcomes are more modest and condition-specific.

Legal and regulatory status

FDA (US): Testosterone is an FDA-approved prescription drug. Its approved indication is testosterone-replacement therapy for male hypogonadism — confirmed low testosterone due to disorders of the testes, pituitary, or hypothalamus (classical/organic hypogonadism). It is not approved for “age-related” (idiopathic) low testosterone. In a March 2015 Drug Safety Communication, the FDA clarified that testosterone products are approved only for men with low testosterone caused by certain medical conditions, that benefit and safety have not been established for low testosterone due solely to aging, and required class-wide labeling changes to that effect.

2025 update: Following the TRAVERSE trial and required post-market ambulatory blood pressure monitoring (ABPM) studies, on February 28, 2025 the FDA issued class-wide labeling changes: it removed the cardiovascular-risk language from the boxed warning, added TRAVERSE results, retained the age-related-hypogonadism Limitation of Use, and added and standardized a warning about increased blood pressure (confirmed class-wide in the ABPM studies).

DEA scheduling: Testosterone and other anabolic-androgenic steroids are Schedule III controlled substances under the Controlled Substances Act, as set by the Anabolic Steroid Control Act of 1990 (expanded by the Anabolic Steroid Control Act of 2004). Non-prescription possession or distribution is a federal crime. For contrast with agents people sometimes lump in: clenbuterol is not FDA-approved for humans and is not a federally scheduled controlled substance, and human growth hormone (HGH) is governed by a dedicated statute, 21 U.S.C. § 333(e), which criminalizes distribution or possession with intent to distribute for non-approved uses.

Anti-doping (WADA): Exogenous testosterone is a Class S1 Anabolic Agent — prohibited at all times (in and out of competition). The 2026 Prohibited List explicitly clarifies that esters of prohibited anabolic agents (e.g., testosterone cypionate, propionate) are prohibited. Detection relies on the steroidal module of the Athlete Biological Passport and on carbon-isotope-ratio (IRMS) testing to distinguish exogenous from endogenous testosterone. (For context, clenbuterol is S1.2; HGH and hCG are S2 Peptide Hormones/Growth Factors.)

Safety

The strength of the efficacy evidence does not make testosterone benign, and supraphysiologic non-medical use is studied far less than replacement therapy and is presumed higher-risk.

Cardiovascular and blood pressure: The large TRAVERSE RCT (5,246 middle-aged and older hypogonadal men at high cardiovascular risk) found testosterone gel non-inferior to placebo for major adverse cardiovascular events (primary endpoint 7.0% vs 7.3%; HR 0.96), but with higher rates of atrial fibrillation, acute kidney injury, and pulmonary embolism (Lincoff et al., NEJM 2023; PMID 37326322). Earlier, the TOM trial in older men with mobility limitations was stopped early for a significantly higher rate of cardiovascular adverse events in the testosterone arm (23 vs 5) (Basaria et al., NEJM 2010; PMID 20592293). FDA-required ABPM studies confirmed a class-wide increase in blood pressure. Net: at replacement doses, major-adverse-cardiovascular-event risk appears not elevated, but the blood-pressure rise, atrial fibrillation, and thromboembolic signals are real.
Lipids: Androgens, especially oral 17α-alkylated forms, lower HDL cholesterol and can raise LDL cholesterol; injectable and transdermal testosterone have smaller lipid effects than 17-aa orals.
Hepatotoxicity: A concern specifically for 17α-alkylated oral androgens such as methyltestosterone — cholestatic jaundice, elevated transaminases, and rare peliosis hepatis and hepatic tumors. Injectable testosterone esters and transdermal testosterone do not carry this 17-aa hepatotoxic risk.
HPTA suppression and infertility: Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis via negative feedback, reducing LH and FSH, which suppresses spermatogenesis (often to azoospermia) and shrinks the testes. Fertility may take months to recover and is not always fully reversible.
Erythrocytosis: Testosterone stimulates erythropoiesis; increased hematocrit and hemoglobin (polycythemia) is among the most common adverse effects and is a recognized thrombotic risk — routine hematocrit monitoring is standard.
Gynecomastia: From aromatization of testosterone to estradiol.
Virilization (in females) and androgenic effects: Voice deepening, hirsutism, clitoral enlargement, and menstrual disruption — often irreversible; acne and male-pattern hair loss can occur in both sexes.
Prostate: Stimulates prostate tissue, can raise PSA and worsen lower-urinary-tract symptoms, and is contraindicated in known prostate or breast cancer in men. Long-term prostate-cancer-incidence data remain limited and reassuring but not definitive.
Other: Mood and behavioral changes and aggression at high doses, fluid retention, worsening of sleep apnea, injection-site reactions, and dependence and withdrawal in long-term high-dose misuse.

Bottom line

Testosterone is an anabolic-androgenic steroid, not a peptide. The human evidence that it increases lean mass and strength — dose-dependently, in young and older men, with and without training — is strong and reproducible, while its benefits on hard clinical and functional endpoints are more modest and condition-specific. It is FDA-approved only for confirmed hypogonadism (not for age-related low testosterone), is a Schedule III controlled substance, and is banned in sport at all times. Its risk profile is real: increased blood pressure, atrial fibrillation and thromboembolic signals, erythrocytosis, suppression of the body’s own testosterone production and fertility, gynecomastia, prostate effects, virilization in women, and — for 17α-alkylated oral forms specifically — hepatotoxicity.

Evidence grade: Strong human.